Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jun 05, 2023 2:51pm
119 Views
Post# 35480950

RE:AESP

RE:AESPGood that ASEP flaunts their product to the investing community to garner a MC that is more than 1/3 of Spectral's with just a small piece of the diagnostic side - with no proposed treatment plan (other than maybe a modified cocktail of antibiotics)

The EAA has been a personalized diagnostic tool (sort of an AI tool) that has been around for 20+ years.  

Higher levels of Endotoxins puts patient more at risk. EAA detects a problem that may be more severe, within 15 min.



But the good news is that this product puts more attention on Severe Sepsis. Asep can't fix the problem so while it may be another companion diagnostic, they will still need PMX (in many cases e.g. gram-negative >.x) in order to treat/cure the patient.

Also acknowledged is the problem of Antibiotic resistent bugs which is a growing problem that will lead to more deaths (again unless there are earlier treatments, and other treatments are approved besides antibiotics)

MM (lay-person perspective)
<< Previous
Bullboard Posts
Next >>